Your browser doesn't support javascript.
loading
A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high-risk neuroblastoma: An International Neuroblastoma Risk Group project.
Moreno, Lucas; Guo, Dongjing; Irwin, Meredith S; Berthold, Frank; Hogarty, Michael; Kamijo, Takehiko; Morgenstern, Daniel; Pasqualini, Claudia; Ash, Shifra; Potschger, Ulrike; Ladenstein, Ruth; Valteau-Couanet, Dominique; Cohn, Susan L; Pearson, Andrew D J; London, Wendy B.
Afiliação
  • Moreno L; Pediatric Hematology and Oncology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
  • Guo D; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts.
  • Irwin MS; Department of Paediatrics, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada.
  • Berthold F; Department of Pediatric Oncology and Hematology, University of Cologne, Cologne, Germany.
  • Hogarty M; Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, Pennsylvania.
  • Kamijo T; Research Institute for Clinical Oncology, Saitama Cancer Center, Saitama, Japan.
  • Morgenstern D; Department of Paediatrics, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada.
  • Pasqualini C; Pediatrics, Institut Gustave Roussy, Paris, France.
  • Ash S; Pediatric Hematology Oncology Center, Schneider Children's Medical Center of Israel, Petah Tikva, Israel.
  • Potschger U; CCRI, Children Cancer Research Institute, Vienna, Austria.
  • Ladenstein R; CCRI, Children Cancer Research Institute, Vienna, Austria.
  • Valteau-Couanet D; Pediatrics, Institut Gustave Roussy, Paris, France.
  • Cohn SL; Department of Pediatrics, University of Chicago, Chicago, Illinois.
  • Pearson ADJ; Division of Clinical Studies, Institute of Cancer Research, Royal Marsden Hospital, Sutton, UK.
  • London WB; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts.
Pediatr Blood Cancer ; 68(3): e28794, 2021 03.
Article em En | MEDLINE | ID: mdl-33205902
BACKGROUND: Long-term outcome remains poor for children with high-risk neuroblastoma (five-year overall survival [OS] ∼50%). Our objectives were to (a) identify prognostic biomarkers and apply them in a nomogram to identify the subgroup of ultra-high-risk patients at highest risk of disease progression/death, for whom novel frontline therapy is urgently needed; and (b) validate the nomogram in an independent cohort. METHODS: A total of 1820 high-risk patients (≥18 months old with metastatic neuroblastoma), diagnosed 1998-2015, from the International Neuroblastoma Risk Groups (INRG) Data Commons were analyzed in a retrospective cohort study. Using multivariable Cox regression of OS from diagnosis, a nomogram was created from prognostic biomarkers to predict three-year OS. External validation was performed using the SIOPEN HR-NBL1 trial cohort (n = 521), evidenced by receiver operating characteristic curves. RESULTS: The nomogram, including MYCN status (P < 0.0001), lactate dehydrogenase (LDH) (P = 0.0007), and presence of bone marrow metastases (P = 0.004), had robust performance and was validated. Applying the nomogram at diagnosis (a) gives prognosis of an individual patient and (b) identifies patients predicted to have poor outcome (three-year OS was 30% ± 5% for patients with a nomogram score of > 82 points; 58% ± 1% for those ≤82 points). Median follow-up time was 5.5 years (range, 0-14.1). CONCLUSIONS: In high-risk neuroblastoma, a novel, publicly available nomogram using prognostic biomarkers (MYCN status, LDH, presence of bone marrow metastases; https://neuroblastoma.shinyapps.io/High-Risk-Neuroblastoma-Nomogram/) has the flexibility to apply a clinically suitable and context-specific cutoff to identify patients at highest risk of death. This will facilitate testing urgently needed new frontline treatment options to improve outcome for these children.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores Tumorais / Neoplasias da Medula Óssea / Nomogramas / Proteína Proto-Oncogênica N-Myc / L-Lactato Desidrogenase / Neuroblastoma Tipo de estudo: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Child, preschool / Female / Humans / Male Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores Tumorais / Neoplasias da Medula Óssea / Nomogramas / Proteína Proto-Oncogênica N-Myc / L-Lactato Desidrogenase / Neuroblastoma Tipo de estudo: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Child, preschool / Female / Humans / Male Idioma: En Ano de publicação: 2021 Tipo de documento: Article